Keeping patients at the forefront of cancer research
A global team of AstraZeneca employees will spend this week in Texas for the annual San Antonio Breast Cancer Symposium.
This meeting is a chance for scientists from biopharma and academia to interact with health care professionals and other researchers to exchange information that helps us better understand and develop treatment options for breast cancer.
For more than 30 years, AstraZeneca has researched, discovered, and developed medicines to fight cancer. One of the areas the AstraZeneca team is focused on is metastatic breast cancer. As we explained in this post, metastatic breast cancer—a form of advanced breast cancer also referred to as stage IV breast cancer—is diagnosed when a breast cancer has spread to other parts of the body.
Patients are at the forefront of our efforts to understand and develop treatment options for metastatic breast cancer.
“We all have loved ones that we hope never get breast cancer in the first place. For those who are unfortunately affected by breast cancer, we want to provide innovative medicines as well as information so that they and their doctors can make the best possible treatment decisions,” said Joe Cordaro, Executive Director of Development at AstraZeneca.
“One of the best ways to keep patients front and center is to hear from them directly about what it is like to face a metastatic breast cancer diagnosis, and to get their thoughts on how we can support them during a journey with cancer,” according to Eric Vogel, who leads the AstraZeneca oncology sales and marketing teams.
So as we head to San Antonio, we wanted to once again share these insights from women who are living with metastatic breast cancer.